4.13: Factors Affecting Protein-Drug Binding: Drug Interactions

Drug interactions are a critical aspect of pharmacology and can occur when two or more drugs compete for the same binding site. This competition can result in one drug displacing another, altering the effect of the displaced drug. Drug interactions are complex processes that rely heavily on how much of the displacer drug is present and how strongly it can bind to the same sites as the displaced drug.

Displacement interactions can have varying outcomes, ranging from toxicity to virtually insignificant clinical effects. A classic example is the interaction between phenylbutazone and warfarin. Phenylbutazone can displace warfarin from its binding sites, which leads to an increase in the concentration of free warfarin in the bloodstream. This displacement can result in heightened toxicity due to the increased availability of warfarin.

Indirect interactions also play a significant role in drug interactions. For instance, heparin, a commonly used anticoagulant, triggers an enzyme called lipoprotein lipase. This enzyme metabolizes triglycerides into free fatty acids. When administered, heparin can concurrently reduce the protein binding of certain drugs like propranolol. This effect is attributed to the increased levels of fatty acids that result from the action of heparin.

Competition is not limited to drugs alone; it can also occur between the body's constituents and drugs. Some drugs can impair the binding of bilirubin, a waste product, to albumin, a protein in blood plasma. When this happens, free bilirubin can cross the blood-brain barrier, potentially leading to kernicterus, also known as bilirubin encephalopathy, a type of brain damage that can occur in neonates.

Drugs can also influence protein-binding interactions through allosteric changes in the protein molecule. Allosteric changes refer to structural modifications in a protein that alter its function. Aspirin is a prime example of an allosteric effector. It modifies the ability of albumin to bind non-steroidal anti-inflammatory drugs (NSAIDs) by acetylating a part of the albumin molecule known as the lysine fraction. This modification can change how NSAIDs interact with albumin, leading to potential changes in the drug's effect.

Understanding these multifaceted interactions is crucial for predicting clinical effects and avoiding adverse outcomes.

Drug displacement interactions arise when drugs compete for the same binding site, leading to displacement.

The extent of displacement depends on the concentration and binding site affinity of the displacer drug.

Displacement interactions can result in toxicity or insignificant clinical effects. For instance, phenylbutazone displaces warfarin from its binding sites, escalating free warfarin concentration and toxicity.

Furthermore, indirect interactions can also occur. For example, heparin triggers lipoprotein lipase, metabolizing triglycerides into free fatty acids. Concurrently, it reduces the protein binding of drugs like propranolol due to increased fatty acid levels.

Competition can occur between the body's constituents and drugs. Some drugs hinder bilirubin binding to albumin. The free bilirubin can cross the blood-brain barrier, leading to kernicterus in neonates.

Also, drugs can affect protein-binding interactions through allosteric changes in the protein molecule.      

Aspirin, an allosteric effector, modifies albumin's capacity to bind NSAIDs by acetylating its lysine fraction.